Erritzoe et al., 2023 - Google Patents
Brain serotonin release is reduced in patients with depression: a [11C] Cimbi-36 positron emission tomography study with a d-amphetamine challengeErritzoe et al., 2023
View PDF- Document ID
- 15746472531419499916
- Author
- Erritzoe D
- Godlewska B
- Rizzo G
- Searle G
- Agnorelli C
- Lewis Y
- Ashok A
- Colasanti A
- Boura I
- Farrell C
- Parfitt H
- Howes O
- Passchier J
- Gunn R
- Politis M
- Nutt D
- Cowen P
- Knudsen G
- Rabiner E
- Publication year
- Publication venue
- Biological Psychiatry
External Links
Snippet
Background The serotonin hypothesis of depression proposes that diminished serotonergic (5-HT) neurotransmission is causal in the pathophysiology of the disorder. Although the hypothesis is over 50 years old, there is no firm in vivo evidence for diminished 5-HT …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erritzoe et al. | Brain serotonin release is reduced in patients with depression: a [11C] Cimbi-36 positron emission tomography study with a d-amphetamine challenge | |
| Pietrzak et al. | Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus | |
| Tarumi et al. | Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study | |
| Bloomfield et al. | Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [11C] PBR28 PET brain imaging study | |
| Skogseth et al. | Accuracy of clinical diagnosis of dementia with Lewy bodies versus neuropathology | |
| Jauhar et al. | The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study | |
| Roberts et al. | Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation | |
| Sunwoo et al. | The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with P arkinson's disease | |
| Di Iorio et al. | Evidence for chronically altered serotonin function in the cerebral cortex of female 3, 4-methylenedioxymethamphetamine polydrug users | |
| Cheng et al. | The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders | |
| Weinstein et al. | PET imaging of dopamine-D2 receptor internalization in schizophrenia | |
| Kolla et al. | Single-photon emission computed tomography and positron emission tomography studies of antisocial personality disorder and aggression: a targeted review | |
| Hermens et al. | Hippocampal glutamate is increased and associated with risky drinking in young adults with major depression | |
| Park et al. | Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles | |
| Cid et al. | A novel method of evaluating semantic intrusion errors to distinguish between amyloid positive and negative groups on the Alzheimer's disease continuum | |
| Yen et al. | Reduced dopamine transporter availability and neurocognitive deficits in male patients with alcohol dependence | |
| Wang et al. | Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment | |
| Hernaus et al. | No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder | |
| Swerdlow et al. | Effects of amphetamine on sensorimotor gating and neurocognition in antipsychotic-medicated schizophrenia patients | |
| Shi et al. | Relationship of irisin with disease severity and dopamine uptake in Parkinson's disease patients | |
| Wang et al. | Association of insulin resistance with delirium and CSF biomarkers of Alzheimer’s disease in elderly patients with hip fracture | |
| Pachi et al. | Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers | |
| Koshimori et al. | Astrogliosis marker 11C-SL25. 1188 PET in traumatic brain injury with persistent symptoms | |
| Lyall et al. | Lower region‐specific gray matter volume in females with atypical anorexia nervosa and anorexia nervosa | |
| Xiao et al. | Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F] SynVesT‐1 |